Abeona Therapeutics Inc. Common Stock
ABEOStock
$7.02+19.26%52W
Market Cap$397.26M
P/E5.58x
Div yield—
Beta1.33
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)28.15%
Price vs S&P 500 (4W)24.91%
VGM Score47.44
Market Capitalization$397.26M
P/E Ratio (Annual)5.58x
Earnings Surprise History
Q1 26-0.30est. -0.36
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABEOAbeona Therapeutics Inc. Common Stock | C | F | B | $7.02 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Abeona Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies and plasma-based treatments for rare genetic diseases with significant unmet medical needs. The company's pipeline includes pz-cel, an autologous cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB), and adeno-associated virus (AAV)-based gene therapies for rare ophthalmic diseases. These programs target patient populations with limited treatment options and substantial commercial potential.